201 related articles for article (PubMed ID: 26869716)
1. CD8+CD122+CD49dlow regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity.
Akane K; Kojima S; Mak TW; Shiku H; Suzuki H
Proc Natl Acad Sci U S A; 2016 Mar; 113(9):2460-5. PubMed ID: 26869716
[TBL] [Abstract][Full Text] [Related]
2. Suppression of allograft rejection by CD8+CD122+PD-1+ Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis.
Liu H; Wang Y; Zeng Q; Zeng YQ; Liang CL; Qiu F; Nie H; Dai Z
Oncotarget; 2017 Apr; 8(15):24187-24195. PubMed ID: 28445940
[TBL] [Abstract][Full Text] [Related]
3. CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway.
Chen Z; Han Y; Gu Y; Liu Y; Jiang Z; Zhang M; Cao X
J Immunol; 2013 Jun; 190(12):6145-54. PubMed ID: 23677464
[TBL] [Abstract][Full Text] [Related]
4. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis.
Kilinc MO; Rowswell-Turner RB; Gu T; Virtuoso LP; Egilmez NK
J Immunol; 2009 Dec; 183(12):7656-60. PubMed ID: 19923444
[TBL] [Abstract][Full Text] [Related]
5. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
[TBL] [Abstract][Full Text] [Related]
6. CD8+CD122+ regulatory T cells (Tregs) and CD4+ Tregs cooperatively prevent and cure CD4+ cell-induced colitis.
Endharti AT; Okuno Y; Shi Z; Misawa N; Toyokuni S; Ito M; Isobe K; Suzuki H
J Immunol; 2011 Jan; 186(1):41-52. PubMed ID: 21098236
[TBL] [Abstract][Full Text] [Related]
7. A lack of Fas/FasL signalling leads to disturbances in the antiviral response during ectromelia virus infection.
Bień K; Sobańska Z; Sokołowska J; Bąska P; Nowak Z; Winnicka A; Krzyzowska M
Arch Virol; 2016 Apr; 161(4):913-28. PubMed ID: 26780774
[TBL] [Abstract][Full Text] [Related]
8. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
Benihoud K; Bonardelle D; Bobé P; Kiger N
Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
[TBL] [Abstract][Full Text] [Related]
9. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
11. Role of Fas/FasL signaling in regulation of anti-viral response during HSV-2 vaginal infection in mice.
Krzyzowska M; Orłowski P; Bąska P; Bodera P; Zdanowski R; Stankiewicz W
Immunobiology; 2014 Dec; 219(12):932-43. PubMed ID: 25129477
[TBL] [Abstract][Full Text] [Related]
12. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cells promote inflammation and apoptosis in the liver after sepsis: role of Fas-FasL.
Wesche-Soldato DE; Chung CS; Gregory SH; Salazar-Mather TP; Ayala CA; Ayala A
Am J Pathol; 2007 Jul; 171(1):87-96. PubMed ID: 17591956
[TBL] [Abstract][Full Text] [Related]
14. Suppression of immune responses by CD8 cells. I. Superantigen-activated CD8 cells induce unidirectional Fas-mediated apoptosis of antigen-activated CD4 cells.
Noble A; Pestano GA; Cantor H
J Immunol; 1998 Jan; 160(2):559-65. PubMed ID: 9551888
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
16. Murine antithymocyte globulin T-cell depletion is mediated predominantly by macrophages, but the Fas/FasL pathway selectively targets regulatory T cells.
Neff KS; Richards SM; Williams JM; Garman RD; Ruzek MC
Transplantation; 2011 Sep; 92(5):523-8. PubMed ID: 21804441
[TBL] [Abstract][Full Text] [Related]
17. The Fas death pathway controls coordinated expansions of type 1 CD8 and type 2 CD4 T cells in Trypanosoma cruzi infection.
Guillermo LV; Silva EM; Ribeiro-Gomes FL; De Meis J; Pereira WF; Yagita H; DosReis GA; Lopes MF
J Leukoc Biol; 2007 Apr; 81(4):942-51. PubMed ID: 17261545
[TBL] [Abstract][Full Text] [Related]
18. Transient local depletion of Foxp3+ regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death.
Reardon C; Wang A; McKay DM
J Immunol; 2008 Jun; 180(12):8316-26. PubMed ID: 18523298
[TBL] [Abstract][Full Text] [Related]
19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
20. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.
Aruna BV; Ben-David H; Sela M; Mozes E
Immunology; 2006 Jul; 118(3):413-24. PubMed ID: 16827902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
